Progress of ferroptosis mechanism and application in lung cancer therapy

Abstract

Abstract: Ferroptosis is a newly discovered mechanism of cell death characterized by accumulation of iron dependent lipid peroxidation and reactive oxygen species, which is different from apoptosis, necrosis and autophagy in morphology and biochemical findings. It is involved in the occurrence and development of lung cancer, so inducing ferroptosis seems to become a new strategy for anti-lung cancer therapy. This review includes the followings: mechanism of ferroptosis from the aspects of iron metabolism, amino acid and glutathione metabolism and lipid metabolism; its effects on lung cancer occurrence and progression, chemotherapy resistance, radiation resistance and immunotherapy respectively, in order to update information on ferroptosis and thus provides a new direction and new strategy for lung cancer treatment.

Key words: programmed cell death, ferroptosis, biochemical process, lung cancer, lung cancer therapy

CLC Number:

R734.2

XU Fei, CHEN Wei-da, GUO Ming-hao, CHEN Ze-tao. Progress of ferroptosis mechanism and application in lung cancer therapy[J]. Basic & Clinical Medicine, 2021, 41(3): 442-447.

References

[1] Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149: 1060-1072.
[2] Torti SV, Manz DH, Paul BT, et al. Iron and cancer[J]. Annu Rev Nutr, 2018, 38: 97-125.
[3] Torti SV, Torti FM. Iron and cancer: more ore to be mined[J]. Nat Rev Cancer, 2013, 13: 342-355.
[4] Stockwell BR, Friedmann AJ, Bayir H, et al. Ferropto-sis: a regulated cell death nexus linking metabolism, redox biology, and disease[J]. Cell, 2017, 171: 273-285.
[5] Li C, Deng X, Zhang W, et al. Novel allosteric activators for ferroptosis regulator glutathione peroxidase 4[J]. J Med Chem, 2019, 62: 266-275.
[6] Gao M, Monian P, Quadri N, et al. Glutaminolysis and transferrin regulate ferroptosis[J]. Mol Cell, 2015, 59: 298-308.
[7] Doll S, Proneth B, Tyurina YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition[J]. Nat Chem Biol, 2017, 13: 91-98.
[8] Stoyanovsky DA, Tyurina YY, Shrivastava I, et al. Iron catalysis of lipid peroxidation in ferroptosis: regulated enzymatic or random free radical reaction?[J]. Free Radic Biol Med, 2019, 133: 153-161.
[9] Sukiennicki GM, Marciniak W, Muszyńska M, et al. Iron levels, genes involved in iron metabolism and antioxida-tive processes and lung cancer incidence[J]. PLoS One, 2019, 14: 1-13.
[10] Wen CP, Lee JH, Tai YP, et al. High serum iron is associated with increased cancer risk[J]. Cancer Res, 2014, 74: 6589-6597.
[11] Cai J, Gu B, Cao F, et al. A transferrin-target magnetic/fluorescent dual-mode probe significantly enhances the diagnosis of non-small cell lung cancer[J]. Oncotarget, 2016, 7: 40047-40059.
[12] Sun X, Ou Z, Xie M, et al. HSPB1 as a novel regulator of ferroptotic cancer cell death[J]. Oncogene, 2015, 34: 5617-5625.
[13] Ji X, Qian J, Rahman SMJ, et al. xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression[J]. Oncogene, 2018, 37: 5007-5019.
[14] Hu K, Li K, Lv J, et al. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma[J]. J Clin Invest, 2020, 130: 1752-1766.
[15] Lai Y, Zhang Z, Li J, et al. STYK1/NOK correlates with ferroptosis in non-small cell lung carcinoma[J]. Biochem Biophys Res Commun, 2019, 519: 659-666.
[16] Doll S, Freitas FP, Shah R, et al. FSP1 is a glutathione-independent ferroptosis suppressor[J]. Nature, 2019, 575: 693-698.
[17] Sato M, Kusumi R, Hamashima S, et al. The ferroptosis inducer erastin irreversibly inhibits system xc-and synergizes with cisplatin to increase cisplatin's cytotoxicity in cancer cells[J]. Sci Rep, 2018, 8: 1-9.
[18] Li Y, Yan H, Xu X, et al. Erastin/sorafenib induces cisplatin-resistant non-small cell lung cancer cell ferroptosis through inhibition of the Nrf2/xCT pathway[J]. Oncol Lett, 2020, 19: 323-333.
[19] Huang Y, Dai Z, Barbacioru C, et al. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance[J]. Cancer Res, 2005, 65: 7446-7454.
[20] Zhang X, Sui S, Wang L, et al. Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin[J]. J Cell Physiol, 2020, 235: 3425-3437.
[21] Liu Q, Wang K. The induction of ferroptosis by impairing STAT3/Nrf2/GPx4 signaling enhances the sensitivity of osteosarcoma cells to cisplatin[J]. Cell Biol Int, 2019, 43: 1245-1256.
[22] Lei G, Zhang Y, Koppula P, et al. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression[J]. Cell Res, 2020, 30: 146-162.
[23] Pan X, Lin Z, Jiang D, et al. Erastin decreases radioresistance of NSCLC cells partially by inducing GPX4-mediated ferroptosis[J]. Oncol Lett, 2019, 17: 3001-3008.
[24] Tomita K, Fukumoto M, Itoh K, et al. MiR-7-5p is a key factor that controls radioresistance via intracellular Fe(2+) content in clinically relevant radioresistant cells[J]. Biochem Biophys Res Commun, 2019, 518: 712-718.
[25] Wang W, Green M, Choi JE, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy[J]. Nature, 2019, 569: 270-274.